Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Rigel (Nasdaq: RIGL) announced that Raul Rodriguez, president and CEO, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 3:00 PM PT (6:00 PM ET).
The presentation will be available via live webcast and archived recording through Rigel's Investor Relations site at www.rigel.com; investors are advised to connect to the website before the start to allow any required software downloads.
Positive
- None.
Negative
- None.
News Market Reaction 31 Alerts
On the day this news was published, RIGL gained 8.66%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.4% during that session. Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $71M to the company's valuation, bringing the market cap to $891M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: PVLA and ANAB up 3.89% and 3.41%, NRIX slightly up 0.32%, while RZLT and TERN are down 4.98% and 3.98%, indicating RIGL’s move is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Conference appearance | Neutral | +2.8% | Piper Sandler healthcare conference presentation with webcast access details. |
| Nov 17 | Clinical data update | Positive | +1.4% | Publication of final 5-year REZLIDHIA Phase 2 data in R/R mIDH1 AML. |
| Nov 12 | Conference appearance | Neutral | +5.2% | Jefferies Global Healthcare Conference presentation and webcast details. |
| Nov 04 | Earnings update | Positive | -7.4% | Strong Q3 2025 revenues, net income, and raised full‑year guidance. |
| Nov 03 | Scientific meeting data | Positive | -2.9% | Multiple ASH presentations with updated R289 and REZLIDHIA clinical data. |
Conference and data announcements have often coincided with modest positive moves, while strong earnings once saw a negative reaction.
Over the last few months, Rigel has combined solid financial execution with increased visibility. Q3 2025 results reported revenue of $69.5M and net income of $27.9M, followed by raised 2025 revenue guidance. The stock, however, fell 7.41% after that earnings release. In contrast, conference and presentation headlines on Nov 3, Nov 12, and Nov 26, 2025 produced mixed but generally smaller moves, suggesting investors treat such appearances as incremental visibility events rather than major catalysts.
Market Pulse Summary
The stock moved +8.7% in the session following this news. A strong positive reaction aligns with Rigel’s pattern of constructive responses to visibility events. Previous conference announcements in late 2025 coincided with moves of 2.82% and 5.24%, suggesting investors often view such appearances as supportive of the story. However, the negative 7.41% move after strong Q3 earnings shows sentiment can reverse even on good fundamentals, so conference-related strength has not guaranteed durability in the past.
Key Terms
hematologic disorders medical
AI-generated analysis. Not financial advice.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302654554.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
When will Rigel (RIGL) present at the J.P. Morgan Healthcare Conference in 2026?
Who from Rigel (RIGL) will speak at the January 14, 2026 presentation?
How can investors watch Rigel's (RIGL) live webcast for the J.P. Morgan presentation?
Will Rigel (RIGL) provide a recording of the January 14, 2026 J.P. Morgan presentation?
What should viewers do before joining Rigel's (RIGL) live webcast on January 14, 2026?
Is Rigel's (RIGL) J.P. Morgan presentation focused on products or company strategy?
